It would thus be tempting to speculate that anti-GARP:TGF-β1 improves the anti-tumor efficacy of anti-PD-1 by blocking TGF-β1 activation on the surface of GARP+ endothelial cells. The gene discussed is TGFB1; the disease is neoplasm.